Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Inhibition of CPT1A reverses AML1-ETO-induced differentiation blockage by activating BCL-2/MYC signaling and metabolic reprogramming

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYang LiuHWHaoren WangRGRunxia Gu

Discussion

Loading...

Member takes

Overview

Inhibition of CPT1A enhances differentiation of leukemic stem cells in AML, indicating a potential therapeutic strategy against chemoresistance.

Key Points

  • CPT1A inhibition restored differentiation in leukemic stem cells, aiding myeloid lineage commitment.
  • Elevated carnitine levels were linked to poor prognosis in patients with AML characterized by AML1-ETO.
  • Observational analysis included metabolomic profiling and genetic knockouts in AML1/ETO model systems.
  • Study supports targeting metabolic pathways as a strategy to overcome drug resistance in acute myeloid leukemia.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5d4https://doi.org/10.1182/blood-2025-3224
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia2025 · 4 citations
  2. 2Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia2025 · 1 citations
  3. 3PRMT1-mediated metabolic reprogramming promotes leukemogenesis2025 · 2 citations
  4. 4Azin1/tecr reprograms fatty acid metabolism to drive Acute Myeloid Leukemia progression2025
  5. 5Disrupting CXCL12-DPP4-GPC3 axis redistributes leukemia stem cells and confines AML cells within bone marrow niche2025 · 1 citations